LONDON, Nov 9 (Reuters) - Britain expects to have 10 million doses of Pfizer/BioNTech’s candidate COVID-19 vaccine available by the end of the year if regulators approve it, Prime Minister Boris Johnson’s spokesman said on Monday, following positive clinical trial results.
The spokesman said that Britain had now ordered 40 million doses of the candidate vaccine developed by Pfizer and BioNTech, one of six that Britain has agreed supply deals for. (Reporting by Elizabeth Piper, writing by Alistair Smout, editing by Estelle Shirbon)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.